Published in Mol Oncol on September 21, 2013
MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma. Int J Mol Sci (2014) 1.12
MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Res Int (2015) 1.12
MicroRNA (miRNA) in cancer. Cancer Cell Int (2015) 1.06
Genomewide Study of Salivary MicroRNAs for Detection of Oral Cancer. J Dent Res (2014) 0.96
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget (2016) 0.94
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol (2014) 0.93
MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol (2015) 0.92
MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci (2013) 0.90
Circulating cell-free microRNAs as biomarkers for colorectal cancer. Surg Today (2015) 0.88
MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. Biomed Res Int (2015) 0.88
Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev (2015) 0.88
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget (2015) 0.86
Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget (2016) 0.86
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. Biomed Res Int (2015) 0.84
Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers. Int J Mol Sci (2016) 0.83
Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. PLoS One (2015) 0.83
Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo. Oncotarget (2015) 0.82
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol (2016) 0.82
Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma. Sci Rep (2015) 0.81
Circulating microRNA testing for the early diagnosis and follow-up of colorectal cancer patients. Mol Diagn Ther (2014) 0.81
Therapeutic manipulation of angiogenesis with miR-27b. Vasc Cell (2015) 0.80
Diagnostic and prognostic value of miR-106a in colorectal cancer. Oncotarget (2016) 0.80
Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. PLoS One (2016) 0.76
Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. Oncol Lett (2016) 0.75
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. Am J Cancer Res (2016) 0.75
Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. Int J Mol Sci (2017) 0.75
The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: a meta-analysis. Oncotarget (2017) 0.75
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas. Mol Oncol (2014) 0.78
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics J (2015) 0.75